The Glucagon-Like Peptide 1 (GLP-1) Agonist market is currently undergoing a historic transformation. What was once a niche class of drugs for blood sugar control has evolved into a global pharmacological phenomenon, primarily driven by the "Weight Loss Revolution" and the broadening of therapeutic indications to include cardiovascular and renal health. https://www.databridgemarketresearch.com/reports/global-glucagon-like-peptide-1-glp-1-agonists-market